Transcatheter Mitral Valve-in-Valve Implantation Applying a Long Pre-Curved Sheath for Patients with Degenerated Bioprosthetic Mitral Valve

Backgrounds: Percutaneous transseptal transcatheter mitral valve-in-valve implantation (TMViV) has become an alternative minimally invasive treatment choice for patients with degenerated mitral bioprosthesis and high surgical risk. However, transseptal approach is more technically challenging than t...

Full description

Bibliographic Details
Main Authors: Yang Liu, Mengen Zhai, Chennian Xu, Lanlan Li, Yu Mao, Yanyan Ma, Ping Jin, Wuchao Xue, Jian Yang
Format: Article
Language:English
Published: IMR Press 2023-02-01
Series:Reviews in Cardiovascular Medicine
Subjects:
Online Access:https://www.imrpress.com/journal/RCM/24/2/10.31083/j.rcm2402050
_version_ 1797893354078339072
author Yang Liu
Mengen Zhai
Chennian Xu
Lanlan Li
Yu Mao
Yanyan Ma
Ping Jin
Wuchao Xue
Jian Yang
author_facet Yang Liu
Mengen Zhai
Chennian Xu
Lanlan Li
Yu Mao
Yanyan Ma
Ping Jin
Wuchao Xue
Jian Yang
author_sort Yang Liu
collection DOAJ
description Backgrounds: Percutaneous transseptal transcatheter mitral valve-in-valve implantation (TMViV) has become an alternative minimally invasive treatment choice for patients with degenerated mitral bioprosthesis and high surgical risk. However, transseptal approach is more technically challenging than transapical approach in TMViV procedures. Objective: The objective of this study was to introduce the experience of applying long pre-curved sheaths in transseptal TMViV procedures and to evaluate the effect of long pre-curved sheath techniques in TMViV procedures. Methods: Between January 2020 and December 2021, 27 patients with degenerated bioprosthetic mitral valve underwent TMViV procedures using a balloon-expandable valve via the transseptal approach. The regular 14/16F expandable sheath were used for low-profile delivery in first 10 cases, and 22F long pre-curved sheath were used in the next 17 cases during procedures. We retrospectively reviewed the catheter techniques, perioperative characteristics, and prognosis. The median follow-up time was 12 (1–21) months. To further scrutinize our data, we divided the group into the early 10 patients using 14/16F expandable sheath and the subsequent 17 patients with long pre-curved sheath in order to assess the impact of different sheaths and procedural details on outcomes. Results: Procedural success was obtained in all patients with no in-hospital mortality. Seventeen patients received 26 mm prostheses; the remaining ten patients received 29 mm prostheses. Post balloon dilatation was performed in one case. Total procedure time was (96.1 ± 28.2) min, the fluoroscopic time was (27.4 ± 6.5) min, and total contrast volume was (50.7 ± 10.1) mL. One patient received blood transfusion because of hemorrhage at the femoral puncture site. One patient received a permanent pacemaker implantation due to high-degree atrioventricular block at postoperative day 3. There were no other major post-procedure complications and the median length of hospital stay was 4 days. Twenty-five (92.6%) patients improved by ≥1 New York Heart Association (NYHA) functional class at 30 days. In subsequent sub analysis, there were shorter procedural time [(85.2 ± 24.3) vs. (115.2 ± 25.6) min, p = 0.0048] and shorter fluoroscopic time [(24.3 ± 5.2) vs. (31.3 ± 5.1) min, p = 0.0073] in cases with the long pre-curved sheath than ones with regular expandable sheath. The iatrogenic atrial septal defect (ASD) closure was performed because of the transeptal large right to left shunt in 2 cases with regular expandable sheath, but no patient needed intraoperative ASD closure in cases with the long pre-curved sheath. Conclusions: Transseptal TMViV using long pre-curved sheath could simplify transseptal approach with reliable outcomes for patients of degenerated mitral bioprosthesis.
first_indexed 2024-04-10T06:51:31Z
format Article
id doaj.art-3e2e8731699e4c03b3c9224ce674c8b0
institution Directory Open Access Journal
issn 1530-6550
language English
last_indexed 2024-04-10T06:51:31Z
publishDate 2023-02-01
publisher IMR Press
record_format Article
series Reviews in Cardiovascular Medicine
spelling doaj.art-3e2e8731699e4c03b3c9224ce674c8b02023-02-28T08:09:00ZengIMR PressReviews in Cardiovascular Medicine1530-65502023-02-012425010.31083/j.rcm2402050S1530-6550(22)00723-2Transcatheter Mitral Valve-in-Valve Implantation Applying a Long Pre-Curved Sheath for Patients with Degenerated Bioprosthetic Mitral ValveYang Liu0Mengen Zhai1Chennian Xu2Lanlan Li3Yu Mao4Yanyan Ma5Ping Jin6Wuchao Xue7Jian Yang8Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 710032 Xi’an, Shaanxi, ChinaDepartment of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 710032 Xi’an, Shaanxi, ChinaDepartment of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 710032 Xi’an, Shaanxi, ChinaDepartment of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 710032 Xi’an, Shaanxi, ChinaDepartment of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 710032 Xi’an, Shaanxi, ChinaDepartment of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 710032 Xi’an, Shaanxi, ChinaDepartment of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 710032 Xi’an, Shaanxi, ChinaDepartment of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 710032 Xi’an, Shaanxi, ChinaDepartment of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 710032 Xi’an, Shaanxi, ChinaBackgrounds: Percutaneous transseptal transcatheter mitral valve-in-valve implantation (TMViV) has become an alternative minimally invasive treatment choice for patients with degenerated mitral bioprosthesis and high surgical risk. However, transseptal approach is more technically challenging than transapical approach in TMViV procedures. Objective: The objective of this study was to introduce the experience of applying long pre-curved sheaths in transseptal TMViV procedures and to evaluate the effect of long pre-curved sheath techniques in TMViV procedures. Methods: Between January 2020 and December 2021, 27 patients with degenerated bioprosthetic mitral valve underwent TMViV procedures using a balloon-expandable valve via the transseptal approach. The regular 14/16F expandable sheath were used for low-profile delivery in first 10 cases, and 22F long pre-curved sheath were used in the next 17 cases during procedures. We retrospectively reviewed the catheter techniques, perioperative characteristics, and prognosis. The median follow-up time was 12 (1–21) months. To further scrutinize our data, we divided the group into the early 10 patients using 14/16F expandable sheath and the subsequent 17 patients with long pre-curved sheath in order to assess the impact of different sheaths and procedural details on outcomes. Results: Procedural success was obtained in all patients with no in-hospital mortality. Seventeen patients received 26 mm prostheses; the remaining ten patients received 29 mm prostheses. Post balloon dilatation was performed in one case. Total procedure time was (96.1 ± 28.2) min, the fluoroscopic time was (27.4 ± 6.5) min, and total contrast volume was (50.7 ± 10.1) mL. One patient received blood transfusion because of hemorrhage at the femoral puncture site. One patient received a permanent pacemaker implantation due to high-degree atrioventricular block at postoperative day 3. There were no other major post-procedure complications and the median length of hospital stay was 4 days. Twenty-five (92.6%) patients improved by ≥1 New York Heart Association (NYHA) functional class at 30 days. In subsequent sub analysis, there were shorter procedural time [(85.2 ± 24.3) vs. (115.2 ± 25.6) min, p = 0.0048] and shorter fluoroscopic time [(24.3 ± 5.2) vs. (31.3 ± 5.1) min, p = 0.0073] in cases with the long pre-curved sheath than ones with regular expandable sheath. The iatrogenic atrial septal defect (ASD) closure was performed because of the transeptal large right to left shunt in 2 cases with regular expandable sheath, but no patient needed intraoperative ASD closure in cases with the long pre-curved sheath. Conclusions: Transseptal TMViV using long pre-curved sheath could simplify transseptal approach with reliable outcomes for patients of degenerated mitral bioprosthesis.https://www.imrpress.com/journal/RCM/24/2/10.31083/j.rcm2402050mitral valvetranscatheter valve implantationdegenerated bioprosthesisvalve-in-valve proceduresintervention
spellingShingle Yang Liu
Mengen Zhai
Chennian Xu
Lanlan Li
Yu Mao
Yanyan Ma
Ping Jin
Wuchao Xue
Jian Yang
Transcatheter Mitral Valve-in-Valve Implantation Applying a Long Pre-Curved Sheath for Patients with Degenerated Bioprosthetic Mitral Valve
Reviews in Cardiovascular Medicine
mitral valve
transcatheter valve implantation
degenerated bioprosthesis
valve-in-valve procedures
intervention
title Transcatheter Mitral Valve-in-Valve Implantation Applying a Long Pre-Curved Sheath for Patients with Degenerated Bioprosthetic Mitral Valve
title_full Transcatheter Mitral Valve-in-Valve Implantation Applying a Long Pre-Curved Sheath for Patients with Degenerated Bioprosthetic Mitral Valve
title_fullStr Transcatheter Mitral Valve-in-Valve Implantation Applying a Long Pre-Curved Sheath for Patients with Degenerated Bioprosthetic Mitral Valve
title_full_unstemmed Transcatheter Mitral Valve-in-Valve Implantation Applying a Long Pre-Curved Sheath for Patients with Degenerated Bioprosthetic Mitral Valve
title_short Transcatheter Mitral Valve-in-Valve Implantation Applying a Long Pre-Curved Sheath for Patients with Degenerated Bioprosthetic Mitral Valve
title_sort transcatheter mitral valve in valve implantation applying a long pre curved sheath for patients with degenerated bioprosthetic mitral valve
topic mitral valve
transcatheter valve implantation
degenerated bioprosthesis
valve-in-valve procedures
intervention
url https://www.imrpress.com/journal/RCM/24/2/10.31083/j.rcm2402050
work_keys_str_mv AT yangliu transcathetermitralvalveinvalveimplantationapplyingalongprecurvedsheathforpatientswithdegeneratedbioprostheticmitralvalve
AT mengenzhai transcathetermitralvalveinvalveimplantationapplyingalongprecurvedsheathforpatientswithdegeneratedbioprostheticmitralvalve
AT chennianxu transcathetermitralvalveinvalveimplantationapplyingalongprecurvedsheathforpatientswithdegeneratedbioprostheticmitralvalve
AT lanlanli transcathetermitralvalveinvalveimplantationapplyingalongprecurvedsheathforpatientswithdegeneratedbioprostheticmitralvalve
AT yumao transcathetermitralvalveinvalveimplantationapplyingalongprecurvedsheathforpatientswithdegeneratedbioprostheticmitralvalve
AT yanyanma transcathetermitralvalveinvalveimplantationapplyingalongprecurvedsheathforpatientswithdegeneratedbioprostheticmitralvalve
AT pingjin transcathetermitralvalveinvalveimplantationapplyingalongprecurvedsheathforpatientswithdegeneratedbioprostheticmitralvalve
AT wuchaoxue transcathetermitralvalveinvalveimplantationapplyingalongprecurvedsheathforpatientswithdegeneratedbioprostheticmitralvalve
AT jianyang transcathetermitralvalveinvalveimplantationapplyingalongprecurvedsheathforpatientswithdegeneratedbioprostheticmitralvalve